Literature DB >> 32804271

Depression profile in malignancy patients attending otorhinolaryngology clinic.

Meera Niranjan Khadilkar1, K Keshava Pai2, Thripthi Rai3, Vijendra Shenoy3, Deviprasad Dosemane3, Sushmitha Kabekkodu3.   

Abstract

PURPOSE: Patients with malignancy quite often suffer from physical as well as psychological symptoms due to the shattering diagnosis, and prolonged, incapacitating management. The frequency of the depressive disorder in malignancy is around 8-40%. The present study aims at analysing the socio-demographic profile and magnitude of depressive disorders in patients with malignancy.
METHODS: A cross-sectional study was conducted in malignancy patients attending an Ear Nose Throat department using the PHQ-9 questionnaire.
RESULTS: Total PHQ-9 score ranged from 0 to 19; the mean score was 8.46. Major depressive disorder was seen in 4 (8%) cases, while other depressive disorder occurred in 22 (44%) cases. Mild severity of symptoms was noted in 15 (30%) of the patients. High statistical significance was noted between PHQ-9 score for MDD and other depressive disorder (p value < 0.001).
CONCLUSION: The profile of depressive disorders in malignancy varies; PHQ-9 can be used as a good tool for early detection.

Entities:  

Keywords:  Depression; Malignancy; Otorhinolaryngology; PHQ-9

Mesh:

Year:  2020        PMID: 32804271      PMCID: PMC7826301          DOI: 10.1007/s00405-020-06289-w

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  9 in total

1.  Screening for depression in cancer patients using the PHQ-9: The accuracy of somatic compared to non-somatic items.

Authors:  Miriam Grapp; Valentin Terhoeven; Christoph Nikendei; Hans-Christoph Friederich; Imad Maatouk
Journal:  J Affect Disord       Date:  2019-05-13       Impact factor: 4.839

2.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

3.  The Hospital Anxiety and Depression Scale (HADS) and the 9-item Patient Health Questionnaire (PHQ-9) as screening instruments for depression in patients with cancer.

Authors:  Tim J Hartung; Michael Friedrich; Christoffer Johansen; Hans-Ulrich Wittchen; Herman Faller; Uwe Koch; Elmar Brähler; Martin Härter; Monika Keller; Holger Schulz; Karl Wegscheider; Joachim Weis; Anja Mehnert
Journal:  Cancer       Date:  2017-06-27       Impact factor: 6.860

4.  Depression profile in cancer patients and patients without a chronic somatic disease.

Authors:  Christoph Nikendei; Valentin Terhoeven; Johannes C Ehrenthal; Imad Maatouk; Beate Wild; Wolfgang Herzog; Hans-Christoph Friederich
Journal:  Psychooncology       Date:  2017-07-03       Impact factor: 3.894

5.  Assessing depression in a geriatric cancer population.

Authors:  Rebecca M Saracino; Mark I Weinberger; Andrew J Roth; Arti Hurria; Christian J Nelson
Journal:  Psychooncology       Date:  2016-05-16       Impact factor: 3.894

Review 6.  Depression and Survival in Patients With Head and Neck Cancer: A Systematic Review.

Authors:  Brittany Barber; Jace Dergousoff; Linda Slater; Jeffrey Harris; Daniel O'Connell; Hamdy El-Hakim; Vincent L Biron; Nicholas Mitchell; Hadi Seikaly
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-03       Impact factor: 6.223

7.  Risk of depressive disorder among patients with head and neck cancer: A nationwide population-based study.

Authors:  Chao-Yueh Fan; Hsing-Lung Chao; Chun-Shu Lin; Wen-Yen Huang; Chang-Ming Chen; Kuen-Tze Lin; Cheng-Li Lin; Chia-Hung Kao
Journal:  Head Neck       Date:  2017-09-30       Impact factor: 3.147

8.  Depression and survival in head and neck cancer patients.

Authors:  Katherine Rieke; Kendra K Schmid; William Lydiatt; Julia Houfek; Eugene Boilesen; Shinobu Watanabe-Galloway
Journal:  Oral Oncol       Date:  2017-01-01       Impact factor: 5.972

9.  The value of distinct depressive symptoms (PHQ-9) to differentiate depression severity in cancer survivors: An item response approach.

Authors:  Loek J van der Donk; Esmée A Bickel; Wim P Krijnen; K Annika Tovote; Robbert Sanderman; Maya J Schroevers; Joke Fleer
Journal:  Psychooncology       Date:  2019-08-30       Impact factor: 3.894

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.